Consistent with these findings, a recent pan-cancer analysis of enzymes, signaling, or transcription factors involved in glucose or FA metabolism showed that CD36 expression was associated with an EMT phenotype and was upregulated in several metastatic tumors [Figure 6]. This evidence concerns the gene CD36 and cancer.